Abstract

According to the World Health Organization, major depressive disorder (MDD) is a mental health condition which affects a significant portion of the worldwide population and is projected to become the leading cause of disability by 2020. There are several treatment options for the diagnosis of depression, with the most popular being antidepressant drugs such as the selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs); and electroconvulsive therapy (ECT). The significant drawbacks to the current treatments are the extended timeframe required for drugs to reach therapeutic efficacy and resistance to ECT over time. These disadvantages can lead to increased risk of self-harm and suicidal tendencies. A drug with fast onset and efficacy in treating depression can improve patient's quality of life.

Author Details

Sergio A. Quinones, DNAP, CRNA

Sigma Membership

Non-member

Type

Other Graduate Paper

Format Type

Text-based Document

Study Design/Type

Other

Research Approach

Pilot/Exploratory Study

Keywords:

Ketamine, Depression, Antidepressants, Infusions, Mechanisms, Safety

Advisor

Pecka, Shannon

Degree

Doctoral-Other

Degree Grantor

Bryan College of Health Sciences

Degree Year

2018

Rights Holder

All rights reserved by the author(s) and/or publisher(s) listed in this item record unless relinquished in whole or part by a rights notation or a Creative Commons License present in this item record.

All permission requests should be directed accordingly and not to the Sigma Repository.

All submitting authors or publishers have affirmed that when using material in their work where they do not own copyright, they have obtained permission of the copyright holder prior to submission and the rights holder has been acknowledged as necessary.

Review Type

Faculty Approved: Degree-based Submission

Acquisition

Proxy-submission

Full Text of Presentation

wf_yes

Download

Share

COinS